SEARCH

SEARCH BY CITATION

References

  • 1
    Choi C, Cho C, Kim G, Park K, Jo M, Lee C. Stereotactic radiation therapy of localized prostate cancer using cyberknife. Int J Radiat Oncol Biol Phys 2007; 69: S375
  • 2
    Fuller DB, Naithoh J, Lee C, Hardy S, Jin H. Virtual HDRSM Cyberknife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008; 70: 15881597
  • 3
    King CR, Brooks JD, Gill H. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73: 10431048
  • 4
    Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009; 8: 387392
  • 5
    Meier R, Cotrutz C. MRI-planned stereotactic body radiotherapy for organ-confined prostate cancer: feasibility and early results. Int J Radiat Oncol Biol Phys 2009; 75: S2339
  • 6
    Aluwini S, Van Rooij P, Hoogeman M et al. Cyberknife stereotactic radiotherapy as monotherapy for low to intermediate stage prostate cancer: early experience, feasibility and tolerance. J Endourol 2010; 24: 865869
  • 7
    Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 2010; 9: 575582
  • 8
    Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guidedstereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010; 9: 473477
  • 9
    McBride SM, Wong DS, Dombrowski JJ et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012; 118: 36813690
  • 10
    Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011; 6: 3
  • 11
    Katz AJ, Santoro M, Ashley R, Diblasio F. Stereotactic body radiotherapy for low- and Low-Intermediate Risk Prostate Cancer : is there a dose effect. Front Oncol 2011; 1: 49
  • 12
    Kang JK, Cho CK, Chi CW et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011; 97: 4348
  • 13
    King CR, Brooks JD, Gill H, Presti JCJ. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 877882
  • 14
    Jereczek-Fossa BA, Beltramo G, Fariselli L et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 889897
  • 15
    King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2003; 2: 2529
  • 16
    Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer CR. The Cyberknife® robotic radiosurgery system in 2010. Technol Cancer Res Treat 2010; 9: 433452
  • 17
    Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 236246
  • 18
    Hossain S, Xia P, Huang K et al. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78: 5863
  • 19
    Townsend NC, Huth BJ, Ding W et al. Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 2011; 34: 610
  • 20
    Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010; 78: 442448
  • 21
    King CR, Lo A, Kapp DS. Testicular dose from prostate Cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys 2009; 73: 636637
  • 22
    Fuller DB. Testicular dose from prostate cyberknife: a cautionary note in regard to King et al. Int J Radiat Oncol Biol Phys 2009; 73: 637
  • 23
    Parthan A, Pruttivarasin N, Taylor D et al. Cyberknife for prostate cancer: is it cost effective? J Clin Oncol 2011; (Suppl. 7); Abstract 87
  • 24
    Zietman A, Ibbott G. Aclinical approach to technology assessment: how do we and how should we choose the right treatment? Semin Radiat Oncol 2012; 22: 1117
  • 25
    Fraass BA, Moran JM. Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology. Semin Radiat Oncol 2012; 22: 310
  • 26
    Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 613
  • 27
    Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-Dose-Rate Prostate Brachytherapy: an Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer. Am J Clin Oncol 2010; 33: 481488
  • 28
    Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol) 2010; 22: 157172